Short answer
Inhibikase Therapeutics, Inc. (IKT) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 3.02 (Unregistered Sales of Equity Securities). RA Capital exchanged 18,030,000 common shares for a pre-funded warrant covering 18,030,000 shares.
Inhibikase Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.02 · Unregistered Sales of Equity Securities
- RA Capital exchanged 18,030,000 common shares for a pre-funded warrant covering 18,030,000 shares
- Warrant immediately exercisable at $0.001 per share with no expiration date
- Exchange shifts RA Capital’s position from common stock ownership to warrant exposure
- 9.99% beneficial-ownership blocker, adjustable after 61 days up to 19.99%
- Transaction completed without registration under Securities Act Section 3(a)(9)
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibikase Therapeutics, Inc. 8-K filings
Get the next IKT 8-K as it lands
Follow IKT for push alerts, or ask the research agent what this filing means.